You are here

Botox

Whoops! Allergan's bid to shield Botox manufacturing secrets from competitors backfires

Whoops! Allergan's bid to shield Botox manufacturing secrets from competitors backfires

Fierce Pharma

Flag link:

AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?

AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?

Fierce Pharma

Flag link:

5 reasons AbbVie bought Allergan, and why they may not be enough

5 reasons AbbVie bought Allergan, and why they may not be enough

Biopharma Dive

diversification

Flag link:

Allergan’s Botox Approved for Pediatric Limb Spasticity Amid Split-Up Rumors

Allergan’s Botox Approved for Pediatric Limb Spasticity Amid Split-Up Rumors

Endpoints

upper limb spasticity

Flag link:

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan Rises After FDA Accepts License Applications for Botox Supplements

TheStreet.com

Flag link:

Evolus' Botox competitor is here. Will it dent Allergan's sales?

Evolus' Botox competitor is here. Will it dent Allergan's sales?

Fierce Pharma

Flag link:

Even with new competition, Botox can hold its own in growing migraine field: Allergan executives

Even with new competition, Botox can hold its own in growing migraine field: Allergan executives

Fierce Pharma

Teva Pharmaceuticals

Flag link:

Can Botox hang with CGRP in migraine? Allergan says yes; analysts are skeptical

Can Botox hang with CGRP in migraine? Allergan says yes; analysts are skeptical

Fierce Pharma

Teva Pharmaceutical

Flag link:

Could synthetic Botox soothe chronic pain? A new study holds out the possibility

Could synthetic Botox soothe chronic pain? A new study holds out the possibility

Stat

Flag link:

FDA stiff arms Evolus’ rival to Allergan’s blockbuster Botox, but execs promise a snap response

FDA stiff arms Evolus’ rival to Allergan’s blockbuster Botox, but execs promise a snap response

Endpoints

Flag link:

Allergan's Botox sets its sights on a new customer: men

Allergan's Botox sets its sights on a new customer: men

Medical Marketing and Media

DTC advertising

Flag link:

Botox Biosimilar in Development by Mylan and Revance Therapeutics

Botox Biosimilar in Development by Mylan and Revance Therapeutics

Xtalks

Revance Therapeutics

Flag link:

Mylan teams up with Revance on biosimilar for Botox

Mylan teams up with Revance on biosimilar for Botox

Reuters

Flag link:

Will Allergan cannibalize Botox with ubrogepant?

Will Allergan cannibalize Botox with ubrogepant?

Biopharma Dive

Flag link:

Evolus says its Botox biosimilar could be delayed by FDA issues with Daewoong plant

Evolus says its Botox biosimilar could be delayed by FDA issues with Daewoong plant

Fierce Pharma

drug manufacturing

Flag link:

Look out, Allergan: Doctor surveys show the 'Botox competitive threat is real'

Look out, Allergan: Doctor surveys show the 'Botox competitive threat is real'

Fierce Pharma

Revance Therapeutics

Flag link:

Boasting a late-stage Botox me-too, Evolus files for $75M IPO

Boasting a late-stage Botox me-too, Evolus files for $75M IPO

Endpoints

Flag link:

Settle down, Allergan investors. Botox's market share is safe, analysts say

Settle down, Allergan investors. Botox's market share is safe, analysts say

Fierce Pharma

wrinkle treatment

Flag link:

Watch out Allergan: Revance’s wrinkle-reducer beats Botox in PhIII trials

Watch out Allergan: Revance’s wrinkle-reducer beats Botox in PhIII trials

Endpoints

clinical trials

wrinkle treatments

Flag link:

Pages